Protomer Technologies Inc. Receives an Investment From JDRF T1D Fund Following a Lead Equity Investment by Lilly

PASADENA, Calif.--(BUSINESS WIRE)--Protomer Technologies Inc. (“Protomer”), the biopharmaceutical company today announces the completion of an investment by the JDRF T1D Fund following an initial equity investment in Protomer led by Eli Lilly and Company. Protomer is engineering next-generation protein therapeutics that can sense molecular activators in the body. The company’s proprietary Molecular Engineering of Protein Sensors (MEPS) platform enables the development of therapeutic peptides an

Click to view original post